Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Syndrome

Polycystic Ovary Syndrome

Cysts

Ovarian Cysts

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Gonadal Disorders

Endocrine System Diseases

Hypoglycemic Agents

All Drugs and Chemicals

Natriuretic Agents

Reproductive Control Agents

Metformin

Spironolactone

Ethinyl Estradiol

Contraceptive Agents

Contraceptives, Oral

Chlormadinone Acetate

Mineralocorticoid Receptor Antagonists

Mineralocorticoids

Hormones

Hormone Antagonists

Diuretics

Diuretics, Potassium Sparing

Contraceptive Agents, Female

This group will receive an oral contraceptive containing 0,03mg ethynylestradiol and 2mg chlormadinone acetate

The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.

The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg metformin.

oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months

oral contraceptive

Oral contraceptive plus spironolactone

Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin

Oral contraceptive plus metformin

Rui A Ferriani, MD, PhD

Marcos Felipe S de Sa, MD, PhD

Carolina S Vieira, MD, PhD

The purpose of this study to assess early markers of cardiovascular disease in women with polycystic ovary syndrome in use of oral contraceptive containing ethynilestradiol and chlormadinone acetate alone or associated with Spironolactone.

Polycystic ovary syndrome (PCOS) is associated with comorbidities that may contribute to increased risk of cardiovascular disease (CVD). Oral contraceptives (OC) have been the mainstay of PCOS pharmacological therapy for decades. However, in non-hyperandrogenic women, OC use is associated with higher risk of cardiovascular disease, raising concern about a possible worsening of the unfavorable metabolic and cardiovascular profile of PCOS patients. There is lack of evidence about the impact of PCOS pharmacological therapies on cardiovascular risk markers and the long-term safety of these drugs in PCOS has not been established. The aim of this study is to compare the effect of an OC alone or associated with an anti-androgenic drug (spironolactone) on echografic cardiovascular risk markers, metabolic and hemostatic variables.

Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women

Metabolic Effects of Multiple Therapies in Polycystic Ovary Syndrome (PCOS) Women

University of Sao Paulo

Rui Alberto Ferriani

Rare Diseases

Sarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

Antineoplastic Agents

Cisplatin

Ifosfamide

Isophosphamide mustard

Tubulin Modulators

Combretastatin

I.V. infusion followed by administration of cisplatin

OMBRABULIN (AVE8062)

Placebo

Clinical Sciences & Operations

The primary objective of the study is to compare the progression-free survival (PFS) in the 2 treatment arms

The secondary objectives of the study are :

* To compare the overall survival in the 2 treatment arms
* To compare the objective response rate in the 2 treatment arms
* To assess the safety profile of AVE8062 (in combination with the background cisplatin therapy)
* To assess the pharmacokinetics of AVE8062 and its main metabolite, RPR258063, using a population approach, in all patients enrolled in selected centers.

A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies

A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.

Sanofi

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women	NCT00842140	Polycystic Ovar...	oral contracept... Oral contracept... Oral contracept...	18 Years - 35 Years	University of Sao Paulo
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies	NCT00699517	Sarcoma	OMBRABULIN (AVE... Placebo	18 Years -	Sanofi
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies	NCT00699517	Sarcoma	OMBRABULIN (AVE... Placebo	18 Years -	Sanofi
Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women	NCT00842140	Polycystic Ovar...	oral contracept... Oral contracept... Oral contracept...	18 Years - 35 Years	University of Sao Paulo
Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women	NCT00842140	Polycystic Ovar...	oral contracept... Oral contracept... Oral contracept...	18 Years - 35 Years	University of Sao Paulo

Spots Global Cancer Trial Database for endothelium

Every month we try and update this database with for endothelium cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for endothelium

Every month we try and update this database with for endothelium cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for endothelium cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.